Cargando…

Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial

Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women...

Descripción completa

Detalles Bibliográficos
Autores principales: Amooee, Sedigheh, Parsanezhad, Mohammad Ebrahim, Ravanbod Shirazi, Maryam, Alborzi, Saeed, Samsami, Alamtaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research and Clinical Center for Infertility 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941367/
https://www.ncbi.nlm.nih.gov/pubmed/24639797
_version_ 1782305905332715520
author Amooee, Sedigheh
Parsanezhad, Mohammad Ebrahim
Ravanbod Shirazi, Maryam
Alborzi, Saeed
Samsami, Alamtaj
author_facet Amooee, Sedigheh
Parsanezhad, Mohammad Ebrahim
Ravanbod Shirazi, Maryam
Alborzi, Saeed
Samsami, Alamtaj
author_sort Amooee, Sedigheh
collection PubMed
description Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200µg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well. Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500). Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates. Registration ID in IRCT: IRCT201203139281N1
format Online
Article
Text
id pubmed-3941367
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Research and Clinical Center for Infertility
record_format MEDLINE/PubMed
spelling pubmed-39413672014-03-17 Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial Amooee, Sedigheh Parsanezhad, Mohammad Ebrahim Ravanbod Shirazi, Maryam Alborzi, Saeed Samsami, Alamtaj Iran J Reprod Med Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients. Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients. Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200µg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well. Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500). Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates. Registration ID in IRCT: IRCT201203139281N1 Research and Clinical Center for Infertility 2013-08 /pmc/articles/PMC3941367/ /pubmed/24639797 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Amooee, Sedigheh
Parsanezhad, Mohammad Ebrahim
Ravanbod Shirazi, Maryam
Alborzi, Saeed
Samsami, Alamtaj
Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title_full Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title_fullStr Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title_full_unstemmed Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title_short Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial
title_sort metformin versus chromium picolinate in clomiphene citrate-resistant patients with pcos: a double-blind randomized clinical trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941367/
https://www.ncbi.nlm.nih.gov/pubmed/24639797
work_keys_str_mv AT amooeesedigheh metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial
AT parsanezhadmohammadebrahim metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial
AT ravanbodshirazimaryam metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial
AT alborzisaeed metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial
AT samsamialamtaj metforminversuschromiumpicolinateinclomiphenecitrateresistantpatientswithpcosadoubleblindrandomizedclinicaltrial